Navigation Links
Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
Date:2/1/2012

BOONTON, N.J., Feb. 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has received the 2012 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2011 clinical advances in the oral delivery of peptides. 

This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug delivery key opinion leaders, at the 16th annual DDP conference, held in Las Vegas, Nevada, January 25-27 2012.  This industry achievement award honors Unigene as the Company that has made the greatest contribution to the field of drug delivery throughout 2011.

Ashleigh Palmer, President and CEO, Unigene Laboratories, commented, "As the pharmaceutical industry's largest, longest running and most-respected drug delivery conference, acknowledgement from the DDP provides an exclamation point to Unigene's transformational 2011, which was marked by numerous business, clinical and technological successes." 

Dr. Nozer Mehta, Unigene's Vice President, Research and Development, said, "Among our achievements in 2011, Unigene saw two of its late-stage oral peptide programs successfully advance in the clinic and serve to validate our proprietary oral delivery technology platform; OSTORA™, our oral calcitonin licensed to Tarsa Therapeutics, successfully completed a pivotal Phase 3 study and is targeted for an NDA submission by year-end 2012 and our oral PTH analog, for which we reported a successful outcome in a Phase 2 study with statistically significant results at the end of 2011, and are currently seeking a licensing partner.  This progress not only marks major evolutionary steps in the administration of peptide-based therapeutics but is truly representative of the outstanding work by the entire Unigene team.  We are extremely honored to accept the 2012
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
5. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... a leading laboratory services company, recently announced its formation ... as GI Pathology, D-PATH Dermatopathology and OncoMetrix. ... CEO of Poplar Healthcare, "we felt it was imperative ... individual companies could belong, while still maintaining their unique ...
... Stem Cell Assurance, Inc. (SCLZ.PK) (the "Company") ... "BioRestorative Therapies, Inc."  The Company,s new web site address ... been advised by the Financial Industry Regulatory Authority (FINRA) ... will change from "SCLZ" to "BRTX" thirty days following ...
... Aug. 17, 2011 Planet Biopharmaceuticals, Inc. and its ... pharmaceutical company focused on providing products for allergy and ... Ph.D. has been named as the company,s Executive Chairman ... Officer on August 29, 2011. Odlaug will replace William ...
Cached Biology Technology:Poplar Healthcare Forms Parent Company, Launches New Web Site 2Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc. 2Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman 2
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2
... an estimated 665,000 deaths, mostly among African children. Now, ... for the world,s most useful antimalarial drug, artemisinin, giving ... cost of the live-saving drug in the future. , ... been slow due to high production costs of artemisinin. ...
... a hormone released by the lining of the stomach that ... obesity -- in fact, a vaccine that lowers ghrelin levels ... treatment for obesity. However, many people eat as a ... its effectiveness as a treatment for obesity may be reduced. ...
... pose considerable health threats to humans, and the heavy metal ... are exposed to it through plant-derived foods such as grains ... can reduce the amount of Cd found in the food ... in the Cell Press journal Trends in Plant Science ...
Cached Biology News:IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug 2Low ghrelin -- reducing appetite at the cost of increased stress? 2Studies shed light on how to reduce the amount of toxins in plant-derived foods 2
... for arraying proteins of interest with ... equipment. DiscoverLight Protein Array Kits allow ... cell lysate or antibody in a ... specially designed nitrocellulose membranes with a ...
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
Request Info...
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: